Literature DB >> 16395976

How much intravenous contrast is needed in FDG-PET/CT?

K Strobel1, C M Thuerl, T F Hany.   

Abstract

Intravenous, iodinated contrast agents are used routinely for CT (ceCT) imaging but only applied reluctantly for FDG-PET/CT due to possible artefacts. Only for few oncological PET/CT indications, the role of IV contrast agent has been clarified. Essentially, if any knowledge regarding vascular structures or tumour invasion into adjacent structures are needed, a ceCT as part of the combined PET/CT exam should be implemented. However, for some indications like lymphoma, contrast seems not to be necessary. Therefore, imaging procedures for the use of IV contrast for PET/CT have to be adapted individually for each FDG-PET/CT indication to especially reduce unnecessary radiation burden to the patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16395976

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  4 in total

1.  Putting 'clear' into nuclear medicine: a decade of PET/CT development.

Authors:  Thomas Beyer; David W Townsend
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

2.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.

Authors:  Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-01       Impact factor: 9.236

3.  Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Authors:  Paul Flechsig; Ramin Rastgoo; Clemens Kratochwil; Ole Martin; Tim Holland-Letz; Alexander Harms; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

4.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.